Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02338037 · ClinicalTrials.gov registry record · Early Phase 1
Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors
A Early Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT02338037 is a Early Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 8 participants.
The verdict
NCT02338037, a Early Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This pilot trial studies the brain concentration of eribulin mesylate in treating patients with primary or metastatic brain tumors. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Collecting small samples of brain fluids may help determine how well eribulin mesylate concentrates into the brain tumor.
Interventions
- PROCEDURE Biopsy
- PROCEDURE Therapeutic Conventional Surgery
- PROCEDURE Microdialysis
- OTHER Pharmacological Study
- DRUG Eribulin Mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-05-19 |
| Est. Completion | 2024-03-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02338037
The ClinicalTrials.gov registry entry for NCT02338037 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biopsy is the first listed.
NCT02338037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02338037 about?
NCT02338037 is a clinical study titled "Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors". This pilot trial studies the brain concentration of eribulin mesylate in treating patients with primary or metastatic brain tumors. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from divi...
What is the current status of trial NCT02338037?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2015-05-19. Estimated completion is 2024-03-15.
What interventions are being tested in trial NCT02338037?
The interventions under investigation include: Biopsy (PROCEDURE), Therapeutic Conventional Surgery (PROCEDURE), Microdialysis (PROCEDURE), Pharmacological Study (OTHER), Eribulin Mesylate (DRUG).
Who is sponsoring clinical trial NCT02338037?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.